Cargando…

Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study

BACKGROUND: Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this study was to assess whether patients with MS are more likely to develop low BMD...

Descripción completa

Detalles Bibliográficos
Autores principales: Simonsen, Cecilia Smith, Celius, Elisabeth Gulowsen, Brunborg, Cathrine, Tallaksen, Chantal, Eriksen, Erik Fink, Holmøy, Trygve, Moen, Stine Marit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139093/
https://www.ncbi.nlm.nih.gov/pubmed/27919248
http://dx.doi.org/10.1186/s12883-016-0771-4
_version_ 1782472181470461952
author Simonsen, Cecilia Smith
Celius, Elisabeth Gulowsen
Brunborg, Cathrine
Tallaksen, Chantal
Eriksen, Erik Fink
Holmøy, Trygve
Moen, Stine Marit
author_facet Simonsen, Cecilia Smith
Celius, Elisabeth Gulowsen
Brunborg, Cathrine
Tallaksen, Chantal
Eriksen, Erik Fink
Holmøy, Trygve
Moen, Stine Marit
author_sort Simonsen, Cecilia Smith
collection PubMed
description BACKGROUND: Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this study was to assess whether patients with MS are more likely to develop low BMD (osteopenia or osteoporosis) than patients with the non-inflammatory neurological diseases Hereditary Spastic Paraplegia (HSP) and Hereditary Ataxia (HA). METHODS: We performed a case control study comparing BMD (spine, hip and total body) and biochemical measures of bone metabolism in 91 MS patients and 77 patients with HSP or HA, matched for age, gender and disability. Both patient groups had lived with the disease for at least 10 years. RESULTS: In total 74.7% of the patients with MS and 75.3% of the patients with HSP or HA had osteopenia (−2.5 < T- score < −1.0) or osteoporosis (T- score ≤ −2.5) in one or more sites. Osteoporosis was more common in patients with MS than with HSP/HA (44.0 vs 20.8%, p =0.001). This difference was not significant after correction for confounders (p = 0.07), nor were any of the biochemical markers. CONCLUSION: Most patients with disabling neurological diseases like MS and HSP/HA develop osteopenia or osteoporosis. MS patients had osteoporosis more frequently than HA/HSP patients, though the difference was not significant after adjusting for confounders. Osteoporosis and bone health should be considered in all patients with both inflammatory and degenerative chronic neurological diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-016-0771-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5139093
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51390932016-12-15 Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study Simonsen, Cecilia Smith Celius, Elisabeth Gulowsen Brunborg, Cathrine Tallaksen, Chantal Eriksen, Erik Fink Holmøy, Trygve Moen, Stine Marit BMC Neurol Research Article BACKGROUND: Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this study was to assess whether patients with MS are more likely to develop low BMD (osteopenia or osteoporosis) than patients with the non-inflammatory neurological diseases Hereditary Spastic Paraplegia (HSP) and Hereditary Ataxia (HA). METHODS: We performed a case control study comparing BMD (spine, hip and total body) and biochemical measures of bone metabolism in 91 MS patients and 77 patients with HSP or HA, matched for age, gender and disability. Both patient groups had lived with the disease for at least 10 years. RESULTS: In total 74.7% of the patients with MS and 75.3% of the patients with HSP or HA had osteopenia (−2.5 < T- score < −1.0) or osteoporosis (T- score ≤ −2.5) in one or more sites. Osteoporosis was more common in patients with MS than with HSP/HA (44.0 vs 20.8%, p =0.001). This difference was not significant after correction for confounders (p = 0.07), nor were any of the biochemical markers. CONCLUSION: Most patients with disabling neurological diseases like MS and HSP/HA develop osteopenia or osteoporosis. MS patients had osteoporosis more frequently than HA/HSP patients, though the difference was not significant after adjusting for confounders. Osteoporosis and bone health should be considered in all patients with both inflammatory and degenerative chronic neurological diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-016-0771-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-05 /pmc/articles/PMC5139093/ /pubmed/27919248 http://dx.doi.org/10.1186/s12883-016-0771-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Simonsen, Cecilia Smith
Celius, Elisabeth Gulowsen
Brunborg, Cathrine
Tallaksen, Chantal
Eriksen, Erik Fink
Holmøy, Trygve
Moen, Stine Marit
Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title_full Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title_fullStr Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title_full_unstemmed Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title_short Bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
title_sort bone mineral density in patients with multiple sclerosis, hereditary ataxia or hereditary spastic paraplegia after at least 10 years of disease - a case control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139093/
https://www.ncbi.nlm.nih.gov/pubmed/27919248
http://dx.doi.org/10.1186/s12883-016-0771-4
work_keys_str_mv AT simonsenceciliasmith bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT celiuselisabethgulowsen bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT brunborgcathrine bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT tallaksenchantal bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT eriksenerikfink bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT holmøytrygve bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy
AT moenstinemarit bonemineraldensityinpatientswithmultiplesclerosishereditaryataxiaorhereditaryspasticparaplegiaafteratleast10yearsofdiseaseacasecontrolstudy